Second, emerging biologics (e.g., recombinant human bone morphogenetic protein-2, teriparatide) may counteract the detrimental osseous effects of diabetes; stratified analyses could determine whether their benefit is more pronounced in patients exceeding the pre-operative HbA1c threshold. Here, BMP2 is linked to diabetes mellitus.